Improving Patient
Outcomes in
Solid Tumor
Cancer TreatmentBIO300
A New Class of Cancer Drug
COVID-19
BIO300
Preventing long term lung damage caused by inflammation
Keeping America Safe
BIO300
Protecting Civilians, First Responders and Our Military
from Nuclear Accidents and Terrorism
Humanetics News
10.30.2024
Humanetics Advances Development of Novel Radiation Protection Drug with New Study Results
Read More
10.03.2024
Humanetics Corporation Presents at the 2024 Department of Defense Scientific Meeting
Read More
10.01.2024
Humanetics to Participate in the BIO Investor Forum in San Franciscio
Read More
08.13.2024
Uniformed Services University Awards Grant to Support Continued Collaboration with Humanetics to Develop Radiation Countermeasure
Read More
05.31.2024
Humanetics to Present at the BIO International Convention in San Diego
Read More
02.13.2024
Humanetics Presents at Oppenheimer 34th Annual Healthcare Life Science Conference
See Presentation
02.06.2024
Humanetics to Present at Investor and Partnering Conferences
Read More
12.12.2023
Major General (Ret.) Barbara R. Holcomb Joins Board at Humanetics
Read More
11.14.2023
Humanetics Appoints Dr. Colin Chinn as Chief Medical Officer
Read More
09.19.2023
Humanetics Publishes Positive Clinical Trial Results of BIO 300 in Patients with NSCLC
Read More
10.24.2023
Humanetics Receives Funding to Study BIO 300 as Treatment for Idiopathic Pulmonary Fibrosis
Read More
09.06.2023
Humanetics Awarded Contract from Dept. of Defense to Develop First FDA Approved Drug to Prevent Radiation Injury
Read More
05.24.2023
BIO 300 Enhances Efficacy of Radiotherapy Against Lung Tumors in a Nonclinical Model
Read More
08.22.2023
BIO 300 Featured at Military Health System Research Symposium
Read More
02.15.2023
Humanetics Announces Positive Results from Independent Data Monitoring Committee Review of Phase 2 Trial in COVID-19 Patients
Read More
02.07.2023
BIO 300 Demonstrates Protection Against Radiation-Induced Lung Injury
Read More